Astrazeneca Plc $AZN Stock Holdings Cut by Gray Foundation

Gray Foundation cut its position in shares of Astrazeneca Plc (NYSE:AZN) by 50.0% during the 1st quarter, Holdings Channel reports. The firm owned 18,268 shares of the company’s stock after selling 18,269 shares during the period. Astrazeneca comprises 0.9% of Gray Foundation’s investment portfolio, making the stock its 11th largest position. Gray Foundation’s holdings in Astrazeneca were worth $3,603,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. Cornerstone Wealth Group LLC bought a new position in Astrazeneca during the first quarter valued at about $220,000. Border to Coast Pensions Partnership Ltd bought a new stake in Astrazeneca in the first quarter worth about $398,270,000. Pictet Asset Management Holding SA bought a new stake in Astrazeneca in the first quarter worth about $675,263,000. ABN AMRO Bank N.V. lifted its holdings in Astrazeneca by 32,441.5% in the 1st quarter. ABN AMRO Bank N.V. now owns 2,445,171 shares of the company’s stock valued at $482,158,000 after acquiring an additional 2,437,657 shares during the last quarter. Finally, Value Partners Investments Inc. acquired a new stake in Astrazeneca in the 1st quarter valued at about $11,331,000. Institutional investors own 20.35% of the company’s stock.

Astrazeneca Price Performance

AZN stock opened at $188.58 on Monday. Astrazeneca Plc has a one year low of $137.23 and a one year high of $212.71. The firm has a 50-day moving average of $184.66 and a two-hundred day moving average of $187.16. The firm has a market capitalization of $292.47 billion, a PE ratio of 28.32, a P/E/G ratio of 1.64 and a beta of 0.25. The company has a current ratio of 0.91, a quick ratio of 0.71 and a debt-to-equity ratio of 0.52.

Astrazeneca (NYSE:AZN) last released its earnings results on Wednesday, April 29th. The company reported $2.58 earnings per share for the quarter, topping the consensus estimate of $2.52 by $0.06. Astrazeneca had a net margin of 17.19% and a return on equity of 30.86%. The business had revenue of $15.29 billion for the quarter, compared to the consensus estimate of $14.93 billion. On average, analysts forecast that Astrazeneca Plc will post 9.39 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the stock. Sanford C. Bernstein reaffirmed a “buy” rating on shares of Astrazeneca in a research note on Monday, May 4th. TD Cowen reissued a “buy” rating on shares of Astrazeneca in a research note on Wednesday, March 18th. Wall Street Zen upgraded shares of Astrazeneca from a “hold” rating to a “buy” rating in a report on Saturday, May 2nd. DZ Bank upgraded shares of Astrazeneca from a “neutral” rating to a “buy” rating in a research report on Wednesday, April 29th. Finally, Weiss Ratings cut Astrazeneca from a “buy (b)” rating to a “buy (b-)” rating in a report on Thursday, June 18th. Twelve investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, Astrazeneca currently has a consensus rating of “Moderate Buy” and an average price target of $205.33.

Astrazeneca Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.